Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study

NCT00526136 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

735

Enrollment

INDUSTRY

Sponsor class

Conditions

Atrial Fibrillation

Interventions

DRUG: Placebo
DRUG: Vernakalant (oral)

Sponsor

Advanz Pharma